As of 2021, the prevalence of diabetics in the UK totaled 8.2 percent. Type 2 diabetes, highly related to unhealthy lifestyle choices, such as the overconsumption of sugar and a lack of exercise, as well as aging, affects more individuals than type 1 diabetes. Between 2023 and 2024, over 3.5 million people in England were registered with type 2 diabetes, while almost 277 thousand had type 1. Type 1 diabetes Between 2023 and 2024, most people registered with type 1 diabetes in England were aged 40 years and younger, with 44.7 percent. In 2021, the UK was the European country with the second-highest number of children and adolescents with type 1 diabetes after Germany, with over 31,600 cases. Treatment The NHS in the UK provides nine care processes annually to people with diabetes. Blood pressure checks, cholesterol monitoring, and foot surveillance are among those. Figures show that almost half of individuals in England with type 2 diabetes received all nine care processes between 2022 and 2023. This figure totaled 37 percent in the case of patients with type 1 diabetes. The same trend could be observed in Wales in 2021/22, where the share of type 2 diabetics receiving all care processes was double the type 1 patients.

United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 4.280 % in 2017. United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 4.280 % from Dec 2017 (Median) to 2017, with 1 observations. United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Type 2 diabetes is a condition that affects the amount of sugar in a person’s bloodstream and causes it to become too high. This type of diabetes can be caused by risk factors such as obesity and inactivity and, as shown in this figure, type 2 diabetes is more common among older individuals. Between 2023 and 2024, of those registered with type 2 diabetes in England, **** percent were aged between 40 and 64 years. Increasing prevalence of diabetes in England Between 2023 and 2024, there were over *** million people in England who were registered as diabetics. The number of individuals registered with diabetes in England has increased year-on-year since 2008. The vast majority of those registered with diabetes in England are diagnosed with type 2 diabetes, with over *** million, while approximately *** thousand living with type 1 diabetes. Diabetes medication By far the most used drug in England for the treatment of diabetes was metformin hydrochloride with over ** million items used in 2022 alone. Additionally, already in 2018 approximately **** percent of all prescribed drugs in primary care in England were for the treatment of diabetes. The share of prescribed diabetes drugs has steadily increased since 2005.

Between 2023 and 2024, approximately ** percent of individuals registered in England with type 1 diabetes were aged between 40 and 64 years. This statistic displays the distribution of individuals registered with type 1 diabetes in England in 2023/24, by age.

This is an overview of the treatment and demographics of 227,435 adults with type 1 diabetes. From 2019 to 2022 glucose control in people with type 1 diabetes in England and Wales improved while blood pressure control deteriorated. Use of diabetes technology (wearable glucose monitoring devices in England and insulin pumps in England and Wales) was associated with lower glucose levels. Diabetes technology was used less by those in the most deprived groups and in ethnic minorities. 30% of people with type 1 diabetes did not attend specialist care in 2021-22 and were less likely to receive annual checks or achieve treatment targets as recommended by the National Institute for Health and Care Excellence (NICE). There are 3 recommendations for commissioners of care.

The National Diabetes Audit (NDA) and the National Paediatric Diabetes Audit (NPDA) provide a comprehensive view of diabetes care in England and Wales. They measure the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This is the second Young People with Type 2 Diabetes report (1). It aims to document the number of people with type 2 diabetes up to the age of 40 years, their patient characteristics and the diabetes care they receive. This is important because adverse diabetes and cardiovascular outcomes are more common in people who develop type 2 diabetes at an earlier age and it is thought the numbers of affected individuals are increasing (2,3).

Diabetes prevalence (% of population ages 20 to 79) in United Kingdom was reported at 7.4 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. United Kingdom - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Between 2023 and 2024, over ******* percent of all those registered with type 2 diabetes in England were Asian or Asian British. This statistic displays the share of individuals registered with diabetes in England in 2023/24, by ethnicity.

To reduce deaths from diabetes.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

The UK Diabetes Market report segments the industry into Management Devices (Insulin Pump, Insulin Pens, Insulin Syringes, Jet Injectors), Monitoring Devices (Self-monitoring Blood Glucose, Continuous Glucose Monitoring), and End User (Hospital/Clinics, Home/Personal). The report provides historical data for five years and forecasts for the next five years.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

Between 2023 and 2024, both type 1 and type 2 diabetes were more prevalent among men than women in England. In this period, for example, **** percent of those with type 2 diabetes were male, compared with **** percent of women. This statistic displays the distribution of individuals registered with diabetes in England in 2023/24, by gender.

The UK Diabetes Drugs Market report segments the industry into Insulins (Basal Or Long Acting Insulins, Bolus Or Fast Acting Insulins, and more), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, and more), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and more), Combination Drugs (Insulin Combinations, and more).

SUMMARYThis analysis, designed and executed by Ribble Rivers Trust, identifies areas across England with the greatest levels of diabetes mellitus in persons (aged 17+). Please read the below information to gain a full understanding of what the data shows and how it should be interpreted.ANALYSIS METHODOLOGYThe analysis was carried out using Quality and Outcomes Framework (QOF) data, derived from NHS Digital, relating to diabetes mellitus in persons (aged 17+).This information was recorded at the GP practice level. However, GP catchment areas are not mutually exclusive: they overlap, with some areas covered by 30+ GP practices. Therefore, to increase the clarity and usability of the data, the GP-level statistics were converted into statistics based on Middle Layer Super Output Area (MSOA) census boundaries.The percentage of each MSOA’s population (aged 17+) with diabetes mellitus was estimated. This was achieved by calculating a weighted average based on:The percentage of the MSOA area that was covered by each GP practice’s catchment areaOf the GPs that covered part of that MSOA: the percentage of registered patients that have that illness The estimated percentage of each MSOA’s population with diabetes mellitus was then combined with Office for National Statistics Mid-Year Population Estimates (2019) data for MSOAs, to estimate the number of people in each MSOA with depression, within the relevant age range.Each MSOA was assigned a relative score between 1 and 0 (1 = worst, 0 = best) based on:A) the PERCENTAGE of the population within that MSOA who are estimated to have diabetes mellitusB) the NUMBER of people within that MSOA who are estimated to have diabetes mellitusAn average of scores A & B was taken, and converted to a relative score between 1 and 0 (1= worst, 0 = best). The closer to 1 the score, the greater both the number and percentage of the population in the MSOA that are estimated to have diabetes mellitus, compared to other MSOAs. In other words, those are areas where it’s estimated a large number of people suffer from diabetes mellitus, and where those people make up a large percentage of the population, indicating there is a real issue with diabetes mellitus within the population and the investment of resources to address that issue could have the greatest benefits.LIMITATIONS1. GP data for the financial year 1st April 2018 – 31st March 2019 was used in preference to data for the financial year 1st April 2019 – 31st March 2020, as the onset of the COVID19 pandemic during the latter year could have affected the reporting of medical statistics by GPs. However, for 53 GPs (out of 7670) that did not submit data in 2018/19, data from 2019/20 was used instead. Note also that some GPs (997 out of 7670) did not submit data in either year. This dataset should be viewed in conjunction with the ‘Health and wellbeing statistics (GP-level, England): Missing data and potential outliers’ dataset, to determine areas where data from 2019/20 was used, where one or more GPs did not submit data in either year, or where there were large discrepancies between the 2018/19 and 2019/20 data (differences in statistics that were > mean +/- 1 St.Dev.), which suggests erroneous data in one of those years (it was not feasible for this study to investigate this further), and thus where data should be interpreted with caution. Note also that there are some rural areas (with little or no population) that do not officially fall into any GP catchment area (although this will not affect the results of this analysis if there are no people living in those areas).2. Although all of the obesity/inactivity-related illnesses listed can be caused or exacerbated by inactivity and obesity, it was not possible to distinguish from the data the cause of the illnesses in patients: obesity and inactivity are highly unlikely to be the cause of all cases of each illness. By combining the data with data relating to levels of obesity and inactivity in adults and children (see the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset), we can identify where obesity/inactivity could be a contributing factor, and where interventions to reduce obesity and increase activity could be most beneficial for the health of the local population.3. It was not feasible to incorporate ultra-fine-scale geographic distribution of populations that are registered with each GP practice or who live within each MSOA. Populations might be concentrated in certain areas of a GP practice’s catchment area or MSOA and relatively sparse in other areas. Therefore, the dataset should be used to identify general areas where there are high levels of diabetes mellitus, rather than interpreting the boundaries between areas as ‘hard’ boundaries that mark definite divisions between areas with differing levels of diabetes mellitus.TO BE VIEWED IN COMBINATION WITH:This dataset should be viewed alongside the following datasets, which highlight areas of missing data and potential outliers in the data:Health and wellbeing statistics (GP-level, England): Missing data and potential outliersLevels of obesity, inactivity and associated illnesses (England): Missing dataDOWNLOADING THIS DATATo access this data on your desktop GIS, download the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset.DATA SOURCESThis dataset was produced using:Quality and Outcomes Framework data: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital.GP Catchment Outlines. Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital. Data was cleaned by Ribble Rivers Trust before use.COPYRIGHT NOTICEThe reproduction of this data must be accompanied by the following statement:© Ribble Rivers Trust 2021. Analysis carried out using data that is: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital.CaBA HEALTH & WELLBEING EVIDENCE BASEThis dataset forms part of the wider CaBA Health and Wellbeing Evidence Base.

In 2017/18, there were almost 3.2 million people in England who were diagnosed with diabetes. The number of individuals registered with diabetes in England has increased year-on-year since 2008. Overall, the number of people with diabetes has increased by 44 percent in the ten-year interval shown.

Breakdown of diabetes types

The vast majority of those registered with diabetes in England are diagnosed with type 2 diabetes, with over 2.9 million registered with type 2. There were approximately 243 thousand living with type 1 diabetes.

Diabetes medication

By far the most commonly used drug in England for the treatment of diabetes was metformin hydrochloride with over 21.8 million items used in 2018 alone. Additionally, in 2018 approximately five percent of all prescribed drugs in primary care in England were for the treatment of diabetes. The share of prescribed diabetes drugs has steadily increased since 2005.

The percentage of patients aged 17 or over with diabetes mellitus, as recorded on practice disease registers.

Note on ward level data This data is GP practice level data taken from Fingertips and converted to wards using our Fingertips GP to Ward Lookup Matrix for Birmingham and Solihull dataset. This dataset uses the GP census to allocate an approximate percentage of their patients to each ward based on the citizens home address.

Rationale Diabetes mellitus is one of the common endocrine diseases affecting all age groups, with over three million people in the UK having the condition. Effective control and monitoring can reduce mortality and morbidity. Much of the management and monitoring of diabetic patients, particularly patients with Type 2 diabetes, is undertaken by the GP and members of the primary care team.

Definition of numerator Patients aged 17+ years with diabetes mellitus.

Definition of denominator Total number of patients aged 17+ years registered with the practice.

Caveats None

Diabetes prevalence of United Kingdom rocketed by 42.31% from 5.2 % in 2011 to 7.4 % in 2024. Since the 42.31% surge in 2024, diabetes prevalence remained constant by 0.00% in 2024. Diabetes prevalence refers to the percentage of people aged 20-79 years who have type 1 or type 2 diabetes.

To reduce deaths from diabetes.